Transcription of Jubilant Life Sciences Limited - jubl.com
{{id}} {{{paragraph}}}
Investor PresentationNovember 2020 Jubilant life Sciences LimitedDisclaimerImportantDisclaimerThis presentation(the Presentation ,orthe document )hasbeenpreparedbyJubilantLifeSciencesLi mited(the Company ) ,inwholeorinpart, ,reproduced,distributed,orotherwisediscl osedorpassedontoothers,inwholeorinpart,b yanymeans, ,neithertheCompany,noritsassociatesandaf filiates,noranyoftheirrespectiveofficers ,directors,advisors,undertakeanyobligati ontoprovidetotherecipient(a)accesstoanya dditionalinformationortoupdatethisdocume nt,or(b) forward-looking ,includingstatementsrelatingtofuturestat us,events,prospectsorcircumstances,inclu dingbutnotlimitedtostatementsaboutplansa ndobjectives,outlook,theprogressandresul tsofresearchanddevelopment,potentialprod uctcharacteristicsanduses, ,includingfuturechangesordevelopmentsint heCompany sbusiness,itscompetitiveenvironment,itsa bilitytoimplementitsstrategiesandinitiat ives,respondtoindustrychangesandthepolit ical,economic, ,fromtimetotime,makeadditionalwrittenand oralforwardlookingstatements,includingst atementscontainedinthecompany , ,offeringcircularorofferingmemorandumora nofferinvitationorasolicitationofanyoffe rtopurchaseorsell,anysecuritiesoftheComp any,andshouldnotbeconsideredorconstruedi nanymannerwhatsoeverasarecommendationtha tanypersonshouldsubscribefororpurchasean yofCompany' ,expectations,estimates
USD 1.3 billion integrated global pharmaceuticals and life sciences company Strong position in Specialty Pharmaceuticals –Radiopharma and Allergy Therapy Products, CMO of sterile injectables 6 USFDA approved manufacturing facilities including 4 in North America and 2 in India; 5 state-of-the-art LSI mfg. facilities in India Expertise in chemistry and manufacturing …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}